Nasdaq:US$13.40 (+0.13) | HKEX:HK$21.30 (+0.25) | AIM:£2.08 (-0.01)
搜索
新闻中心及演示文稿
上一篇文章   |   下一篇文章
演示文稿, 科学出版物 | 2014-06-03

ASCO 2014: First-in-Human Phase I study of a selective c-Met inhibitor AZD6094 (savolitinib) in patients with advanced solid tumors